Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab
in patients with advanced CLL who failed to respond, or have progressed following a prior
response, to a fludarabine regimen.